Clinical Trials Logo

Filter by:
  • Active, not recruiting  
  • « Prev · Page [17]
NCT ID: NCT00508547 Active, not recruiting - Psoriasis Clinical Trials

Psoriasis Longitudinal Assessment and Registry

PSOLAR
Start date: June 21, 2007
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients receiving other therapies, such as non-biologic and other biologic agents. The registry also evaluates patient and disease characteristics, including patient-reported assessment of psoriatic arthritis (PsA); and clinical and quality of life outcomes.

NCT ID: NCT00104676 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Start date: November 26, 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III non-seminomatous germ cell tumors.

NCT ID: NCT00099437 Active, not recruiting - Breast Cancer Clinical Trials

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

CONFIRM
Start date: February 13, 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.

NCT ID: NCT00005584 Active, not recruiting - Lymphoma Clinical Trials

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Start date: October 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy with or without radiation therapy in treating patients who have Hodgkin's lymphoma.

NCT ID: NCT00003681 Active, not recruiting - Anemia Clinical Trials

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Start date: August 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. Epoetin alfa may stimulate red blood cell production and be an effective treatment for anemia in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine with or without epoetin alfa in treating patients who have myelodysplastic syndrome.

NCT ID: NCT00003643 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Combination Chemotherapy in Treating Men With Germ Cell Cancer

Start date: October 1998
Phase: Phase 2/Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy may be more effective for germ cell cancer. PURPOSE: This randomized phase II/III trial is studying two different regimens of combination chemotherapy and comparing how well they work in treating men with germ cell cancer.

NCT ID: NCT00002763 Active, not recruiting - Melanoma (Skin) Clinical Trials

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Start date: April 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of high- or low-dose interferon alfa with that of no further therapy following surgery in treating patients who have stage III melanoma.